HLA B27, HLA b Leader, Psoriatic Arthritis
Conditions
Keywords
Psoriatic arthritis, HLA b leader, HLA B27
Brief summary
Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule. Given this association, these diseases are classically regarded as disorders of adaptive immunity. In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.
Interventions
BIOLOGICALblood test
Addition of an extra tube for blood tests (a single tube for genetic research), enabling phenotyping of the HLA B27 and HLA B leader genes.
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* For the "Patient" group: * Patient over 18 years of age * Patient affiliated to a social security scheme * Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie. * For the "control" group: * Individuals over 18 years of age * Individual affiliated to a social security scheme * Individual having agreed to participate in the study * Individuals with no inflammatory or autoimmune diseases
Exclusion criteria
* Patient or control not understanding French * Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort. * Patient or control objecting to participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prevalence of HLA B leader in both groups | 1 year | prevalence of HLA B leader in patients with psoriatic rheumatism compared to the healthy group by autoimmune disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of HLAB27 gene in both groups | 1 year | Prevalence of HLAB27 gene in patients with psoriatic rheumatism compared to the healthy group free from autoimmune disease |
| prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism patient group | 1 year | prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism in patients with different disease conditions |
Countries
France
Contacts
CONTACTVincent Goeb, Pr
Outcome results
None listed